Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions

Abstract No : 9580

Abstract Type : Poster Session

Indication : NSCLC with EGFR exon 20 insertions

Intervention : TAK-788

Company : Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Technology : Small molecule


A total of 99 pts were included, n=28 TAK-788 and n=71 RWD; mean age 62/65 y; male 25%/46%; Asian 18%/10%; former smoker 39%/45%; brain metastases 43%/34%. In the RWD, there was no consistent regimen for second-line treatment (including 29.6% immuno-oncologic agents, 25.4% EGFR TKI, 10% docetaxel). Baseline characteristics were comparable after weighting. PFS and ORR showed statistically significant improvements with TAK-788 vs RWD (Table). Specifically, after weighting, median PFS for TAK-788 vs RWD is 7.3 vs 3.5 mo, and ORR is 43% vs 13%.


Despite a more heavily pretreated pt population, the efficacy of TAK-788 in pts with refractory NSCLC with EGFR exon 20 insertions appears better than other second-line treatment options used in the real-world setting.


Among pretreated patients with NSCLC with EGFR exon 20 insertions, mobocertinib (TAK-788) demonstrated prolonged PFS and higher ORR compared with other second line treatment options used in real world setting

Refer to Non Small Cell Lung Cancer Market report for detailed Insights.